Comparative Analysis of IL-17 and Resistin Levels in Rheumatoid Arthritis Patients with and without Treatment

Ahmed Abdul-Hassan  Abbas; Saadon Abed  Abdulridha; Mohammad Hadi  Al-Osami; Batool Hassan  Al-Ghurabi

doi:10.63964/5s7bvy54

Authors

Ahmed Abdul-Hassan Abbas Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq Author
Saadon Abed Abdulridha Alkarama Teaching Hospital, Wasit, Iraq Author
Mohammad Hadi Al-Osami Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq Author
Batool Hassan Al-Ghurabi Department of Basic Science, College of Dentistry, University of Baghdad, Baghdad, Iraq Author

DOI:

https://doi.org/10.63964/5s7bvy54

Keywords:

Etanercept; Interleukin-17a; Resistin; Rheumatoid arthritis; Rituximab.

Abstract

Numerous inflamed cells in the joints of people with rheumatoid arthritis (RA) release a variety of inflammatory substances. Resistin and IL-17A levels in patients undergoing and not receiving treatment have been examined in this study. 120 RA patients were studied, and divided into four groups [Group I (30 patients without treatment), group II (thirty patients receiving methotrexate ), while, group III (thirty patients receiving etanercept) and Group IV (30 patients received Rituximab)]. The control consisted of 25 individuals. Blood samples were collected to measure serum levels of IL-17A and resistin by ELISA. Group I's serum levels of IL-17A were considerably greater than those of the controls, as well as those of groups III and IV. Group I also showed a large increase in resistin when compared to controls and group III, but neither group I nor groups II and IV showed any significant changes. Resistin and IL-17 showed a strong positive association. These results show that resistin and IL-17A may be associated with the pathophysiology of RA.